X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sensex Trades on a Dull Note; Pharma Stocks Rally
Thu, 8 Jun 01:30 pm

After opening the day marginally higher, share markets in India erased early gains and are trading below the dotted line. Sectoral indices are trading on a mixed note with stocks in the pharma sector and stocks in the metal sector trading in green, while stocks in the IT sector are leading the losses.

The BSE Sensex is trading down by 44 points (down 0.1%), and the NSE Nifty is trading lower by 11 points (down 0.1%). Meanwhile, the BSE Mid Cap index is trading up by 0.2%, while the BSE Small Cap index is trading up by 0.3% The rupee is trading at 64.36 to the US$.

In news from stocks in the finance sector. HDFC Ltd share price is among the top gainers on the bourses today as the mortgage lender plans to raise Rs 20 billion through a private placement basis today.

HDFC Ltd, which is the largest mortgage lender in the country, said it will issue secured redeemable non-convertible debentures on a private placement basis to raise a total of Rs 20 billion.

The issue opens today, and will close today itself. HDFC said only the persons who are specifically addressed through a communication are eligible to apply for the debentures. No other persons can apply.

The company plans to use the proceeds of the issue to shore up long term capital and for financing/refinancing the housing finance business requirements of the Corporation.

The bonds carrying coupon rate of 7.6% are set to mature in June 2020.

At the time of writing, HDFC ltd share price was trading up by 2%.

Moving on to news from stocks in the pharma space. Most pharma stocks are among the top gainers in the exchanges today, with Dr Reddy's share price leading the gains.

The up move was triggered as Dr Reddys Labs (DRL) announced that it had launched Bivalirudin injection after receiving final approval form the US Food and Drug Administration (USFDA) approval.

Bivalirudin injection is used to prevent blood clots in people suffering from severe chest pain and those who are undergoing angioplasty. It is a therapeutic equivalent generic version of Angiomax for injection.

Citing IMS Health data, Dr Reddys said that Angiomax brand and generic version had sales of about US$ 198 million in the 12 months ended March 2017.

In related news, DRL which was India's second largest pharma company by sales till last year, slipped to the fourth spot in 2016-17, behind Lupin Ltd and Aurobindo Pharma.

The change in the pecking order was marked by the fall of its US generics revenues to below US$ 1 billion level owing to fewer new launches as well as a steep price erosion of the existing products in the US market.

At the time of writing, Dr Reddy's share price was trading up by 4.5%.

Just Released: Multibagger Stocks Guide
(2017 Edition)

In this report, we reveal four proven strategies to picking multibagger stocks.

Well over a million copies of this report have already been claimed over the years.

Go ahead, grab your copy today. It's Free.

NO-SPAM PLEDGE - We will NEVER rent, sell, or give away your e-mail address to anyone for any reason. You can unsubscribe from The 5 Minute WrapUp with a few clicks. Please read our Privacy Policy & Terms Of Use.

The Indian pharmaceutical industry has come under a lot of regulatory pressure in the past few years.

The sector has faced great volatility over the years.

'Safe Haven' Pharma Sector in Decline since 2 Years

We had written about the current predicament of Indian pharma companies in one of the premium editions of the 5 Minute WrapUp:

  • Over the past few years, risk in the US markets has increased. The US Food and Drug Administration has become stricter on products entering US borders. Surprise inspections have increased and companies are being issued warning letters. This has impacted the business and earnings of Indian pharma players, causing major volatility for the sector.

In such a volatile environment, how can earn good returns from the stock markets?

We believe a few super investors could provide the clue. These are the guys who've beaten the markets black and blue and have an eye for multi bagger stocks irrespective of the macro environment.

With respect to which super investors to follow, our Research analysts Kunal and Rohan have could be of great help courtesy their project, The Super Investors of India.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Sensex Trades on a Dull Note; Pharma Stocks Rally". Click here!

  

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Nov 23, 2017 (Close)

MARKET STATS